CRT Improves DFS And OS In Patients With Stage IIIB Cervical Cancer In Long-Term Follow-Up To Phase 3 Trial

Cancer Therapy Advisor (1/7, Lawrence) reports researchers found in a long-term follow-up of a phase 3 trial that “in addition to improving disease-free survival (DFS), chemoradiotherapy (CRT) resulted in an overall survival (OS) benefit for patients with stage IIIB cervical cancer.” The researchers say the results “reinforce the evidence that CRT for the treatment of stage IIIB (International Federation of Gynecology and Obstetrics 2009) squamous cell carcinoma of the uterine cervix is associated with significantly improved” survival outcomes compared to radiotherapy alone. The findings were published in Gynecologic Oncology.